<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-033248
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051031
<FILING-DATE>20051031
<DATE-OF-FILING-DATE-CHANGE>20051031
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051164756
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v028012_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-51122</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                October 31, 2005</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font size="2">pSivida Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td>
              </td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                  Finlay</font></div>
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil&#8482;
                  Phase IIb Clinical Trials for Liver Cancer Commence Following Approval
                  by
                  HSA </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
            2
            -</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v028012_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div align="center">
          <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

              <tr bgcolor="#ffffff">
                <td width="50%"><strong><font size="2">ASX/MEDIA RELEASE </font></strong></td>
                <td width="50%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><IMG SRC="logo.jpg"></div>
                </td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="50%">&#160;</td>
                <td width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;31
                    October 2005</strong></font></div>
                </td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="50%">&#160;</td>
                <td width="50%">&#160;&#160;&#160;&#160;
</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>BrachySil&#8482;
        Phase IIb Clinical Trials for Liver Cancer<br>Commence Following Approval by HSA
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>First
        patient in multi-centre dose-profiling study receives treatment in
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Singapore
        General Hospital after approval by the Health Sciences
        Authority</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited (ASX:PSD, NASDAQ:PSDV, XETRA:PSI) is
        very
        pleased to announce that Phase IIb clinical trials have commenced with
        BrachySil&#8482; (32-P BioSilicon&#8482;) as a potential new brachytherapy treatment for
        inoperable primary liver cancer (hepatocellular carcinoma, HCC). The first
        patient has successfully received treatment at Singapore General Hospital
        (&#8220;SGH&#8221;) using a new fine-gauge needle, multi-injection device which will enable
        for the first time, larger and also multiple tumors to be treated. A total
        of 50
        patients will be entered into this multi-centre trial, which will be conducted
        in Singapore, Malaysia and Vietnam. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        study, which was designed in collaboration with SGH and approved by the
        Singaporean regulatory authority (Health Sciences Authority) will determine
        the
        optimal dose of BrachySil&#8482; in treating inoperable HCC. Patients will be
        evaluated up to 12 months after treatment, and the endpoints are based on
        evaluations of patient safety and target tumor responses, as well as overall
        survival.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        study
        is intended to provide pivotal efficacy and safety data to support future
        product registration and approval of BrachySil&#8482; as an effective treatment for
        primary liver cancer. These results are expected to build on the findings
        of a
        Phase IIa study concluded earlier this year on patients with advanced liver
        cancer. In this trial, which was also conducted at the SGH, BrachySil&#8482; was found
        to be both safe and well tolerated. It was also found to reduce significantly
        the size of some tumors treated even on a lower dose as used in the earlier
        trials.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        addition, the Phase IIb trial will include a clinical evaluation of pSivida&#8217;s
        proprietary SIMPL&#8482; implantation system. SIMPL&#8482; is a fine-gauge needle,
        multi-injection device, through which BrachySil&#8482; is injected as a liquid
        suspension directly into tumors under local anesthetic. The device has been
        designed to ensure the effective distribution of the implanted dose from
        a
        single entry point and, for the first time, to enable physicians to treat
        larger
        tumors. This device is expected to be a further significant advantage of
        BrachySil&#8482; over existing brachytherapies as well as assist in expanding the
        application of BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        to other
        solid tumour cancers, in addition to pancreatic cancer for which a phase
        IIa
        trial is currently being planned. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
        Rezos, CEO of pSivida, said, &#8220;This is a highly important clinical development
        milestone in the programme for the successful commercialization of our
        BrachySil&#8482; cancer therapy product. Positive data from this trial is critical to
        our future plans for the commercialization of BrachySil&#8482; in this indication for
        which we are seeking to file for registration in 2007. We believe that the
        encouraging findings in earlier studies will be confirmed and optimized in
        this
        trial, thus providing both a strong foundation for future regulatory filings
        and
        a powerful attraction for commercial partners.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr
        Pierce
        Chow, Lead Investigator and Senior Consultant, Hepatobiliary and General
        Surgery
        at Singapore General Hospital, said, &#8220;We are delighted to continue working with
        pSivida on this exciting and important new product. Primary liver cancer
        is a
        major malignancy and BrachySil&#8482; has so far demonstrated its potential as a safe
        and relatively pain-free treatment. With this new trial, we expect to reaffirm
        the findings reported previously and bring this innovative product closer
        to the
        patients who really need it.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 943 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="left" valign="top" width="28%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Singapore
                  General Hospital</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ms
                  Angela Ng,</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assistant
                  Manager, Corporate Communications </font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 65 6321 4325 </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is a global bio-nanotech company committed to the biomedical sector and the
        development of products in healthcare. The company&#8217;s focus is the development
        and commercialisation of a modified form of silicon (porosified or
        nano-structured silicon) known as BioSilicon&#8482;. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property pertaining to BioSilicon&#8482; for use in or on humans
        and animals. The IP portfolio consists of 29 patent families, 34 granted
        patents
        and over 80 patent applications. The core patent, which recognises BioSilicon&#8482;
        as a biomaterial was granted in the UK in 2000 and in the US in 2001.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
        Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        pSivida
        is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
        Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's strategic partner and largest shareholder is QinetiQ, a leading
        international defence, security and technology company, formed in July 2001
        from
        the UK Government's Defence Evaluation &amp; Research Agency (DERA).&#160;
        QinetiQ was instrumental in discovering BioSilicon(TM) and pSivida enjoys
        a
        strong relationship with it having access to its cutting edge research and
        development facilities. For more information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Singapore
        General Hospital</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Singapore
        General Hospital (SGH) is Singapore&#8217;s oldest and largest tertiary acute care
        hospital and national referral centre. It offers a comprehensive range of
        clinical specialties and support services for the South-East Asia region.
        Annually, 70,000 patients are admitted to the hospital and 600,000 attend
        its
        specialist outpatient clinics. SGH also recognizes research and education
        as
        essential pillars of healthcare. Drawing upon its wealth of resources (clinical
        expertise, modern research facilities, and patient data and specimens), the
        Hospital&#8217;s researchers are pursuing, in an integrated and holistic manner, the
        full range of &#8216;molecules-to-communities&#8217; studies. Extensive teaching and
        educational services are also offered.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.sgh.com.sg</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Notes
        on BrachySil&#8482; and competitive advantages in brachytherapy </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil&#8482;
        is a micron-sized nanostructured silicon particle in which radioactive
        32-phosphorus (32-P) is immobilized. It is administered as a liquid suspension
        through a fine-gauge needle directly into tumors. The procedure takes place
        under local anaesthetic and without the need for shielded rooms or robotic
        injectors, and patients can be discharged the next day. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brachytherapy
        treatment utilising BrachySil&#8482; includes the following potential
        advantages:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="LINE-HEIGHT: 1.25">
            <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Short
                range </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                32-P isotope has a short active range resulting in controlled exposure
                to
                radioactivity and less damage to healthy
                tissue.</font></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="LINE-HEIGHT: 1.25">
            <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Immobilization
                </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                32-P device is immobilized in the tumor, significantly reducing risk
                of
                leakage or systemic side effects.</font></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="LINE-HEIGHT: 1.25">
            <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Ease
                of application </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                BrachySil&#8482; is delivered under local anaesthetic and patients can be
                discharged the next day.</font></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="LINE-HEIGHT: 1.25">
            <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Direct
                delivery </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                BrachySil&#8482; is delivered via fine-gauge needle, minimizing side effects and
                tissue trauma without the need for shielded rooms or robotic injectors
                allowing treatment in hospitals without the need for investment in
                specialised facilities.</font></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="LINE-HEIGHT: 1.25">
            <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Range
                of tumors </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                fine-gauge needle delivery allows potential application to many solid
                tumors, unlike current brachytherapy
                products.</font></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="LINE-HEIGHT: 1.25">
            <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Distribution
                </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                32-P half-life of 14 days allows convenient distribution to hospitals
                and
                application in the patient.</font></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="LINE-HEIGHT: 1.25">
            <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Manufacture
                </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                BioSilicon&#8482; is &#8220;radiation hard&#8221; allowing ease of manufacture of BrachySil&#8482;
                from phosphorus-doped silicon used in the electronics industry without
                the
                need to build costly manufacturing
                facilities.</font></div>
            </td>
          </tr>

      </table>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties. Although we believe that the expectations reflected in such
        forward-looking statements are reasonable at this time, we can give no assurance
        that such expectations will prove to be correct. Given these uncertainties,
        readers are cautioned not to place undue reliance on such forward-looking
        statements. Actual results could differ materially from those anticipated
        in
        these forward-looking statements due to many important factors including:
        our
        failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues. Other reasons are contained in
        cautionary statements in the Registration Statement on Form 20-F filed with
        the
        U.S. Securities and Exchange Commission, including, without limitation, under
        Item&#160;3.D, "Risk Factors" therein. We do not undertake to update any
        oral or
        written forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0W!17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-3HP-SHR
M-B`R,3HQ,SHR,P```````Z`!``,````!``$``*`"``0````!````O:`#``0`
M```!````/``````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```R+````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]52257,MS*@'T-8]@'N:0\N)_-#/3#DS
M)D&.)F02!OPBRH"VTDJM.8[)Q3=CU[K`=IJ<=L.!][2Z"J3NMW-M-)QAZ@=L
MV[_SIC]Q09.?Y?'&$IS/#D%PD(3E&5^,8_-_47")/T=',S,3!QGY69<S'QZA
M+[;"&M`^)6,SJ/7.M2>E5CIG3S]'J&76776CL_#P'>GZ=?\`PV;_`.PJ)?TO
M#.2>L]6:^^ZD@XV-98+*:7#1K\:@,KK;>_\`TUGJ6L_TBL_M#,KH?DVT@B-M
M.,P.%KK3'IT_I`UGN_TG\VS^<_FV/4GWC'QQQBS.8XN'A(,8_O3XOD6&,J)/
MIB.W5S\!W4\7ZSGICL^WJ&,</[3D>NVL&NPV>E1Z;\:JAOZ=K;_T3O\`1+HE
MF]%Z6_"KNR,IS;>HYS_6S;F`[2Z-E=%.[W_9L6K]#1N_XW^<ML6DID1!`U4D
MDJV9U#'PP!9+GN^BQNIC]Y,R988H&>20A$;RDN`)V;*2H8O6<7(L%9#JW.,-
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M`$GL5A9O7NL4]*PPXL=D962[T,/$K.U]UKOH5L=_@V_GVW?X&OWIF2''"4-N
M*)C_`(RK`U/1S7=3OZ=C9'V/'=F9>1>VG#H9]$V/:]X=<]OLIQJV5^I;;^XQ
M0?O_`&@/4@V>JSU-L[=\M]39N]VS?]!:`Q>J4VC)H8P/>T>I7O+I,?1L?:??
ML^CZK=BS;'7'-+G-`N]4$L[;Y'M_SESG.F6/!@P3QSC+#FEZ^'T9(F4I1]N;
M+`7(RO0C;LZ_7#^@I9^]:/P!5CI[6>@'`-C<X@MVQSMT]/VJF<3J>5D,MR16
MQK/HMD^W^6STG;M__7%J,:&-#1)`TDDD_P"<[W+6Y:$\G-9>9,)8X$"$(Y!P
M3EP_I<*V5"(&[)<;U'ZW];QOK3?T7$Q*\MH:!C5-!;8ZQU3;F^I<ZSTF4L<7
M.M=Z?\TNR7GX_P#RL?Z_]Q"M$=?)K9Y2'!PFN*<8GR+=Z%];.N'ZQGH77:*:
M[;-P::@1L>&?:&-GU+6V564_0=]-:W59KZFRVUN^HAI`[$-/O9JN;ZE'_CHX
MD?\`!S_VS<NWR+<"ZS['>YKWN/T-9!C=](?0=M5/XE@&;"(<<<4N*,L?'\DL
M@^6!_O+N6G*Y@DRX9&-]>%KNQ,#J1;?4_;MT>&0UW\G?^[M1^I95N+C>K4`7
M;@/=J-?AM65F8]G2\AEU#R6NDMGG3Z5;_P!]BO\`67!_3PX<.<PCYJC'.8X>
M<O&,'-XXB64X_EF>']7D@V*UCK<3LT/K%UKJ?3_JZWJN&VIUK75FYMC7%NQY
M]-VT,>QV[>^O\Y5\SZV74_4RCKM3:_MEXK8&.#C7ZI=Z>0-H<U^QFR_9^D6E
MD8/[1^K-N%$F_&<QD_O$?HS_`-N;5Y<,Z[-^K^#T*LEUQS7%M?E8&LH_\'OR
M%K<L3+#CD=281,CYQ:7,9)8YFCI*)$?[]]'OLCZQ]7Q_J57UVQE'VZP5OV;7
M>D&6VAC/9ZGJ?S#V_P"$^FKG3/K!99]4QU[/:W>VFVZQE0+6GTW6-:QF\O\`
MI[%4^O-%>/\`4VW'J$5T_9ZV#^2VRIK?R+/I_P#R5N_XBS_S\Y2=/JDSE&9%
MWPXN+_#'5HM^LWUKZIT3J63?@57=+?5;0^RD['U$L]UC6V/>_(IHW_IOT?\`
MU%BT_P#%UD58OU7S,F]VVFC(MLL=S#65U/>[_-:@?5^/_&WS_P#B\R?_``1%
M_P`7F1C8OU4S,G*<&X]-]K[G$2`QM=)?[?SO:B=CYL>._<QR,K)@9>IHM^NO
MUOZE5D]1Z3@U#IN(3O+F[W``;XL=ZU7J6-K]]K,:O]$NI^JGUA_;_2_M3ZQ3
M?4\U7L:9;N`:_?5/N].QCV_37,NZS]8_K%BYK^D55]+Z-0RSU+7M!ML`;+ZM
M-S?5<SZ7I?S/_<FQ6_\`%9!Z3F$"!]H$#_K521&B[%.7NQ'%*49`FY"HZ?N/
M_]'U*VRNJM]MK@RNMI<]QT`:!N<YRY_ZNTV]6RW?6C-:0+FFOI%#Q!IQ2?Y_
M;^;D9_\`.O?_`*#TZ_45KZT9&!]@/2\_(^Q5=599C-RC`8QQ87;;'.VM_2,W
M_2=[U'*^M?U;Z96S';E5W6M:&4XF)^FL,"&5LIHW[?Y/J;$EDB.+4@"/_2=M
M<IDY&[J]U.*T7Y%=P=8)BNJ7>PY5PW>GO_P>.S?DW?Z/T_TJL5CZR=>,VA_0
M>EG_``;2#G6C^59[J^GL=_(WY7_%?35NKZO5T,95C6#'IJ,U5,9HT_Z0ESW.
MMN?_`(6^W]+:J'Q'ESFCCX<<LIQRXQ",HXX_]4E.4/3_`+/_`,;7PD3=>D']
M([_X(=6IMC618_>_ES@-H_LM]VUJFA4,N97MNM]9\_3VANGAM:BJ]$D@$Q,2
M?T95<?\`$XHJ4O->I4YM_P#C)MJP+QBY9VFFXMWM#FXN_;8P_P"#M:WTGKTI
M<_\`\TQ_SK_YR?:C/_<78(_F?LO\]NW?\)]!.!J_)ASXS,0`Z3C(]/2Y/0OJ
MO]8'_6<]>Z\ZH/KW%HJ.[>\L^SU[6M:WTZ:JOWOTJZ3J73'WV#(QW!MPB03$
MQ]%S7#Z+VK224/,8,?,8SCR"XZ$5Z91E':463%$8[X;U))O6[<8=,ZAE6M=G
M6#8W0Z@F/W6AH#6[OWE>ZEBVY.+Z5,;MP.I@0%;24$/A^&&/+CN<O?%9<DY<
M66?^$R&9L'L@PJGTXM53XWL:`8U$KC,#ZC9^/];!U&P4_LRO(LR*FM<=^NZS
M'9Z>S_!7/;^?_@EW22MXXB$(PCM$"(\HL63'&9!D/E/$''^MO2\OJW0KL'#V
M>O8ZLM]0[6PRQECO<`_\UJ#TOZOW-^J(Z#GEK+7TVU6.K.\-+W6.8]D^GNV;
MVO6\DC:CCB9&1W,>#_!?/NF?57ZZ48.5T=V13C].M#W/+"'NL<YNWTZ7.9OH
MIR/\-ZGT/\&M/HGU3SZ?JGG]%SG5U7Y;[',=6XO:W<RH5[I:S_"5>_\`D+KD
MD;*R/+P%;F@8ZG]&3Y_TOZL?7BK!NZ.[)IPNGOWESFD6/=N!W5TN#6NKJN?_
M`#F_WL_Z"V_J/T'J/0\')HSQ6'VVBQGI.+Q&QC(U:S\YBZ5)(DIA@C$@@DF(
MH6;T?__2[KZW[?V,[=]@V[VS^U)]#O\`Z/W^M_HU0^I>W:_;^Q8C3]D;MW_7
MO4]Z^?TDEA^;]'_NGZJ27RJDDO?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*
MJ22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9_^T2?%!H;W1O<VAO
M<"`S+C``.$))300E```````0`````````````````````#A"24T#[0``````
M$`!(`````0`!`$@````!``$X0DE-!"8```````X`````````````/X```#A"
M24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)````
M```````!`#A"24T$"@```````0``.$))32<0```````*``$``````````CA"
M24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``````
M`0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#^```
M````<```_____________________________P/H`````/______________
M______________\#Z`````#_____________________________`^@`````
M_____________________________P/H```X0DE-!`````````(``3A"24T$
M`@``````!``````X0DE-!`@``````!`````!```"0````D``````.$))300>
M```````$`````#A"24T$&@`````#20````8``````````````#P```"]````
M"@!5`&X`=`!I`'0`;`!E`&0`+0`Q`````0`````````````````````````!
M``````````````"]````/``````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````/`````!29VAT;&]N9P```+T````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`#P`````4F=H=&QO;F<```"]`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))300H```````,`````3_P````````.$))3004```````$
M`````CA"24T$#``````,IP````$```"@````,P```>```%^@```,BP`8``'_
MV/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2`
M`````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04
M#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,_\``$0@`,P"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!````
M``````,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+
M$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("
M`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1
M`#\`]52257,MS*@'T-8]@'N:0\N)_-#/3#DS)D&.)F02!OPBRH"VTDJM.8[)
MQ3=CU[K`=IJ<=L.!][2Z"J3NMW-M-)QAZ@=LV[_SIC]Q09.?Y?'&$IS/#D%P
MD(3E&5^,8_-_47")/T=',S,3!QGY69<S'QZA+[;"&M`^)6,SJ/7.M2>E5CIG
M3S]'J&76776CL_#P'>GZ=?\`PV;_`.PJ)?TO#.2>L]6:^^ZD@XV-98+*:7#1
MK\:@,KK;>_\`TUGJ6L_TBL_M#,KH?DVT@B-M.,P.%KK3'IT_I`UGN_TG\VS^
M<_FV/4GWC'QQQBS.8XN'A(,8_O3XOD6&,J)/IB.W5S\!W4\7ZSGICL^WJ&,<
M/[3D>NVL&NPV>E1Z;\:JAOZ=K;_T3O\`1+HEF]%Z6_"KNR,IS;>HYS_6S;F`
M[2Z-E=%.[W_9L6K]#1N_XW^<ML6DID1!`U4DDJV9U#'PP!9+GN^BQNIC]Y,R
M988H&>20A$;RDN`)V;*2H8O6<7(L%9#JW.,-W1!/[NYI1\[*.)1ZH9ZGN#=L
MQS\G*./-X)8I9HY!+'#YI1UX?\'YD\)NJ;"2%C7&_'KN+=F\3MYB?N15-&0E
M$2CK&0$AY20I)9OUAZN[HO2K>H,H.4:W,;Z(<6SO>VKZ366_1W_N*?0NJ.ZO
MTG'ZBZDXSKPXFDDNV[7.K^DYE7[G^C16\0XN&_57%]&^DJ^?F5X&#D9MK7.K
MQJW6O:R"XA@WN#=Q:W=HJG0.O8O7L)^9BUV55LL-1;<&ATM#'S^C?8W;^D23
MQ"Q&]3T=-))))+__T/557S@#BOF($$[HC0C_`$GL5A9O7NL4]*PPXL=D962[
MT,/$K.U]UKOH5L=_@V_GVW?X&OWIF2''"4-N*)C_`(RK`U/1S7=3OZ=C9'V/
M'=F9>1>VG#H9]$V/:]X=<]OLIQJV5^I;;^XQ0?O_`&@/4@V>JSU-L[=\M]39
MN]VS?]!:`Q>J4VC)H8P/>T>I7O+I,?1L?:??L^CZK=BS;'7'-+G-`N]4$L[;
MY'M_SESG.F6/!@P3QSC+#FEZ^'T9(F4I1]N;+`7(RO0C;LZ_7#^@I9^]:/P!
M5CI[6>@'`-C<X@MVQSMT]/VJF<3J>5D,MR16QK/HMD^W^6STG;M__7%J,:&-
M#1)`TDDD_P"<[W+6Y:$\G-9>9,)8X$"$(Y!P3EP_I<*V5"(&[)<;U'ZW];QO
MK3?T7$Q*\MH:!C5-!;8ZQU3;F^I<ZSTF4L<7.M=Z?\TNR7GX_P#RL?Z_]Q"M
M$=?)K9Y2'!PFN*<8GR+=Z%];.N'ZQGH77:*:[;-P::@1L>&?:&-GU+6V564_
M0=]-:W59KZFRVUN^HAI`[$-/O9JN;ZE'_CHXD?\`!S_VS<NWR+<"ZS['>YKW
MN/T-9!C=](?0=M5/XE@&;"(<<<4N*,L?'\DL@^6!_O+N6G*Y@DRX9&-]>%KN
MQ,#J1;?4_;MT>&0UW\G?^[M1^I95N+C>K4`7;@/=J-?AM65F8]G2\AEU#R6N
MDMGG3Z5;_P!]BO\`67!_3PX<.<PCYJC'.8X><O&,'-XXB64X_EF>']7D@V*U
MCK<3LT/K%UKJ?3_JZWJN&VIUK75FYMC7%NQY]-VT,>QV[>^O\Y5\SZV74_4R
MCKM3:_MEXK8&.#C7ZI=Z>0-H<U^QFR_9^D6ED8/[1^K-N%$F_&<QD_O$?HS_
M`-N;5Y<,Z[-^K^#T*LEUQS7%M?E8&LH_\'OR%K<L3+#CD=281,CYQ:7,9)8Y
MFCI*)$?[]]'OLCZQ]7Q_J57UVQE'VZP5OV;7>D&6VAC/9ZGJ?S#V_P"$^FKG
M3/K!99]4QU[/:W>VFVZQE0+6GTW6-:QF\O\`I[%4^O-%>/\`4VW'J$5T_9ZV
M#^2VRIK?R+/I_P#R5N_XBS_S\Y2=/JDSE&9%WPXN+_#'5HM^LWUKZIT3J63?
M@57=+?5;0^RD['U$L]UC6V/>_(IHW_IOT?\`U%BT_P#%UD58OU7S,F]VVFC(
MMLL=S#65U/>[_-:@?5^/_&WS_P#B\R?_``1%_P`7F1C8OU4S,G*<&X]-]K[G
M$2`QM=)?[?SO:B=CYL>._<QR,K)@9>IHM^NOUOZE5D]1Z3@U#IN(3O+F[W``
M;XL=ZU7J6-K]]K,:O]$NI^JGUA_;_2_M3ZQ3?4\U7L:9;N`:_?5/N].QCV_3
M7,NZS]8_K%BYK^D55]+Z-0RSU+7M!ML`;+ZM-S?5<SZ7I?S/_<FQ6_\`%9!Z
M3F$"!]H$#_K521&B[%.7NQ'%*49`FY"HZ?N/_]'U*VRNJM]MK@RNMI<]QT`:
M!N<YRY_ZNTV]6RW?6C-:0+FFOI%#Q!IQ2?Y_;^;D9_\`.O?_`*#TZ_45KZT9
M&!]@/2\_(^Q5=599C-RC`8QQ87;;'.VM_2,W_2=[U'*^M?U;Z96S';E5W6M:
M&4XF)^FL,"&5LIHW[?Y/J;$EDB.+4@"/_2=M<IDY&[J]U.*T7Y%=P=8)BNJ7
M>PY5PW>GO_P>.S?DW?Z/T_TJL5CZR=>,VA_0>EG_``;2#G6C^59[J^GL=_(W
MY7_%?35NKZO5T,95C6#'IJ,U5,9HT_Z0ESW.MN?_`(6^W]+:J'Q'ESFCCX<<
MLIQRXQ",HXX_]4E.4/3_`+/_`,;7PD3=>D']([_X(=6IMC618_>_ES@-H_LM
M]VUJFA4,N97MNM]9\_3VANGAM:BJ]$D@$Q,2?T95<?\`$XHJ4O->I4YM_P#C
M)MJP+QBY9VFFXMWM#FXN_;8P_P"#M:WTGKTI<_\`\TQ_SK_YR?:C/_<78(_F
M?LO\]NW?\)]!.!J_)ASXS,0`Z3C(]/2Y/0OJO]8'_6<]>Z\ZH/KW%HJ.[>\L
M^SU[6M:WTZ:JOWOTJZ3J73'WV#(QW!MPB03$Q]%S7#Z+VK224/,8,?,8SCR"
MXZ$5Z91E':463%$8[X;U))O6[<8=,ZAE6M=G6#8W0Z@F/W6AH#6[OWE>ZEBV
MY.+Z5,;MP.I@0%;24$/A^&&/+CN<O?%9<DY<66?^$R&9L'L@PJGTXM53XWL:
M`8U$KC,#ZC9^/];!U&P4_LRO(LR*FM<=^NZS'9Z>S_!7/;^?_@EW22MXXB$(
MPCM$"(\HL63'&9!D/E/$''^MO2\OJW0KL'#V>O8ZLM]0[6PRQECO<`_\UJ#T
MOZOW-^J(Z#GEK+7TVU6.K.\-+W6.8]D^GNV;VO6\DC:CCB9&1W,>#_!?/NF?
M57ZZ48.5T=V13C].M#W/+"'NL<YNWTZ7.9OHIR/\-ZGT/\&M/HGU3SZ?JGG]
M%SG5U7Y;[',=6XO:W<RH5[I:S_"5>_\`D+KDD;*R/+P%;F@8ZG]&3Y_TOZL?
M7BK!NZ.[)IPNGOWESFD6/=N!W5TN#6NKJN?_`#F_WL_Z"V_J/T'J/0\')HSQ
M6'VVBQGI.+Q&QC(U:S\YBZ5)(DIA@C$@@DF(H6;T?__2[KZW[?V,[=]@V[VS
M^U)]#O\`Z/W^M_HU0^I>W:_;^Q8C3]D;MW_7O4]Z^?TDEA^;]'_NGZJ27RJD
MDO?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J
MI)?*J22GZJ27RJDDI__9`#A"24T$(0``````4P````$!````#P!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!(`00!D`&\`8@!E`"``4`!H`&\`
M=`!O`',`:`!O`'``(`!#`%,````!`#A"24T$!@``````!P`(`````0$`_^$7
M^6AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN
M/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/'@Z>&UP
M;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX;7!T:STG6$U0('1O
M;VQK:70@,RXP+3(X+"!F<F%M97=O<FL@,2XV)SX*/')D9CI21$8@>&UL;G,Z
M<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M
M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C`O)SX*
M"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA,#5F,&4U,2UF
M93-B+3$Q9#DM8C-E-2UC,60T.6)A-F8R,64G"B`@>&UL;G,Z97AI9CTG:'1T
M<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\G/@H@(#QE>&EF.D-O;&]R4W!A
M8V4^,3PO97AI9CI#;VQO<E-P86-E/@H@(#QE>&EF.E!I>&5L6$1I;65N<VEO
M;CXQ.#D\+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(#QE>&EF.E!I>&5L641I
M;65N<VEO;CXV,#PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\+W)D9CI$97-C
M<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA
M,#5F,&4U,2UF93-B+3$Q9#DM8C-E-2UC,60T.6)A-F8R,64G"B`@>&UL;G,Z
M<&1F/2=H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX*(#PO<F1F.D1E
M<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED
M.F$P-68P934Q+69E,V(M,3%D.2UB,V4U+6,Q9#0Y8F$V9C(Q92<*("!X;6QN
M<SIP:&]T;W-H;W`])VAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\G/@H@(#QP:&]T;W-H;W`Z2&ES=&]R>3X\+W!H;W1O<VAO<#I(:7-T;W)Y
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70])W5U:60Z83`U9C!E-3$M9F4S8BTQ,60Y+6(S934M8S%D-#EB839F
M,C%E)PH@('AM;&YS.G1I9F8])VAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q
M+C`O)SX*("`\=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N
M/@H@(#QT:69F.EA297-O;'5T:6]N/C<R+S$\+W1I9F8Z6%)E<V]L=71I;VX^
M"B`@/'1I9F8Z65)E<V]L=71I;VX^-S(O,3PO=&EF9CI94F5S;VQU=&EO;CX*
M("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70])W5U:60Z83`U9C!E-3$M9F4S8BTQ,60Y+6(S934M8S%D-#EB839F
M,C%E)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,#4M,#<M,C94,C$Z,3,Z,C,M,#4Z
M,#`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z36]D:69Y1&%T93XR,#`U+3`W
M+3(V5#(Q.C$S.C(S+3`U.C`P/"]X87`Z36]D:69Y1&%T93X*("`\>&%P.DUE
M=&%D871A1&%T93XR,#`U+3`W+3(V5#(Q.C$S.C(S+3`U.C`P/"]X87`Z365T
M861A=&%$871E/@H@(#QX87`Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P
M($-3(%=I;F1O=W,\+WAA<#I#<F5A=&]R5&]O;#X*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F$P-68P
M934Q+69E,V(M,3%D.2UB,V4U+6,Q9#0Y8F$V9C(Q92<*("!X;6QN<SIX87!-
M33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^"B`@/'AA<$U-
M.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.F$P-68P934P+69E
M,V(M,3%D.2UB,V4U+6,Q9#0Y8F$V9C(Q93PO>&%P34TZ1&]C=6UE;G1)1#X*
M(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2=U=6ED.F$P-68P934Q+69E,V(M,3%D.2UB,V4U+6,Q9#0Y8F$V9C(Q
M92<*("!X;6QN<SID8STG:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\G/@H@(#QD8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@H@/"]R
M9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX;7!M971A/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X
M<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A``
M`&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="
M``````````````````#VU@`!`````-,M2%`@(```````````````````````
M````````````````````````````````````````$6-P<G0```%0````,V1E
M<V,```&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````
M%&=865H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$
M````B'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,`
M``0,````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)4
M4D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N
M,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````
M``````````````````````````````````````````````!865H@````````
M\U$``0````$6S%A96B``````````````````````6%E:(````````&^B```X
M]0```Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/
M9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6
M245#(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````
M`````````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@````````````````````````````!D97-C`````````"Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``
M````````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0`
M`^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S````````
M``$````````````````````````"CP````)S:6<@`````$-25"!C=7)V````
M````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>
M`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`
MT`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2
M`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"
M`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5
M`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#
MX`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-
M!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&
M>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+
M"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)
MY0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA
M"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.
M+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";
M$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,3
M8Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)
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M-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\
MXSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R
M0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(
MD4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW
M3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5
M=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU
M7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-C
MEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW
M:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S
M`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$
M>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#
MNH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QC
MC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5
MR98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=
MGXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I
M-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,X
MLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^
M"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\
MR3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;4
M2=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^O
MX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K
M^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9
M^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B90!D0`````'_
MVP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__`
M`!$(`#P`O0,!$0`"$0$#$0'_W0`$`!C_Q`&B````!@(#`0`````````````'
M"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'`@@!"0`*"Q```@$#
M!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q@1AB
MD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$
M9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6F
MIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"`0,"
M!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S";$D
MP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$A:.S
MP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(
M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$`
M`A$#$0`_`-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=,6Y]T;:V3M[,;MWCN#"[4
MVMM^AGRF=W'N+)T6%P>&QM,NNHK\IE<C-3T-#20KRTDKJH_K[VJL[!44ECY#
MI/=7=K8VTUY>W"0VD:EG=V"JJCB68D``>I/55T?SP[X^6V5R&V_Y;O3^(W)L
M"AK*G%9CYG?(6#<6U/C_``U5+))3UL?5.T<?%2;][KK:9OTU%/\`P[%),H$D
MSQLKDP%I#;@->RT8\$7+?F>`_P!G&13J+/Z][_S9-):^W&S+)8JQ5MPNP\=J
M"IHPAC%)9R,T(TJ&`U=K!N@.[5W3_,*^'_R&^$4>\OF)B/E!B/D]\@L5TOOO
MI:7X_;`ZQP^(P&0Q-1EMP;RV+E]M5.1W53T^QL=325#M65<NH+$9RZ,Z^WXQ
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M.AS0G2:,"`_9\N[M?6\=S:VX:%JT.I1P)'`D'B.DE5_+OI$4M3_#]U//7_;S
MFA@JMO[JAIIJL1,:>.IFI\%65$-.\H`=TBE=4N0C$6((3^\4^Z4[JJ^XMR23
MP&V;F3^0^DR>GY.4N8`CF.S3Q*&E9$`KY5()(%>)`/V'HBV5^&NXOD'EW[[_
M`)E7=VVNT>H-O5=-N?JWXP=:TFYMH?&;!8QUBJ]O;B[%QF<^VWEW-O:3[A?'
M!EHTHXI28TI723P1Y7;M[O>W_+7MS'[IWV^QV/(KV$-Y]9<*T;&"X17AI$5\
M422B1`D`0S,[+&$\3!A"/VRW[FO>RWN#N"7JQ2L(=OM]2V:E3AI=5'G=:<7(
M0=W%&T+87UKW%L+."';>T]G[GVAM'`;9?(8S+9':$6T-A46W,1'3PP18NH:2
MGHZ+'PT3AH4$442P1L1I5?<-^TWWH.5/>CFEN7^5N2.;(;)[%KN+<;W;7M=O
MN(PT:KX,[R%G:42!X@8QK16.*4ZE^\V(;'8JSS6L<$5%\-&4>&`#^$`*JJ!0
M^0Z)C\>]EY7Y:_*.;Y_;U@JZ;J+KK;NX^J_@QM/(0S4[Y+:V=E6D[*^3]=15
M"I+33=P?:B@VR&6-VVI!'5.EZR,C*2=OI8/HE_M209#\_)/]KY^A\^/4+\N6
M<G.'-'^N%>J1L]O&\.UHPH2C8FOJ'(^H';#PK!I9ERIZM*]EW4K=>]^Z]U[W
M[KW28W'O79^SXXI-U;GP.WEG!,`S&5HL>\X!()@BJ9HY)@".2H-O8%YT]SO;
MGVXB@GY^YZVG9DE_L_K+J&W,GD?#61U9Z'CI!IY]*;>RN[LD6MM)(1QTJ33[
M:<.LFW=X;4W?!)5;6W)A-PP0D+/)ALG1Y`0,U]*SBEFD:!FMP'`)]O<F>X_(
M'N+:37W(7.NU[S:QD!VL[F&XT$\`XB=BA/D&`)\NM7%I=6C!;JW>-C_$I%?L
MKQZR[GW-A=G8')[FW%6?887#P"IR%9X*BI\$)ECA#^"EBGJ)/W)5%D1CS[4\
M\<[<M>W/*F]<[<X;C])RUM\0DN)M$DNA"RH#X<2/(W<RBBHQS6E*]:MK::[G
MCMK=-4SF@%0*^?$T'3)L/L?9W9F,J\QLK+?QC'4->V-JJC[+(4/CK4IX*IH?
M'D:6EE>T%2C:E4KZK7N#["WM+[U>VWOCL>X<R>V/,)W'9[6[-M+)X%Q!IF$<
M<I33<11.>R1&U!2N:5J"`_?[=>;;*D-[%HD9:@5!Q4CR)\P>ES[E3I#U[W[K
MW1'_`))_S&_AY\1NPMM]5_(#MAMB[ZW;@<?N;`84;*W]N,5V$RF:R.WJ&L_B
M&U]L9G&TWFR^*GBT2S)(NC45"D,5EO875U&TL$54!I6H&<>I^8Z`?,_N7R7R
M=N5OM/,6[F"_EB$BKX4SU1F90=4<;**LC"A(./2G1X/KS[1]#SJ#E,IC<)C<
MCF<SD*'$X?$4-7E,KE<G504&-QF-H*>2KKLAD*ZJDBIJ.AHJ6)Y)99&6..-2
MS$`$^]@$D`"I/3<LL4$4L\\BI`BEF9B`JJ!4DDX``R2<`9/0>]<=W],=Q_Q;
M_1'VYUEVE_`!0G._Z.]][7WK_!AD_NOX<<K_`';RF2_AXK_LIO#YM'E\3Z;Z
M6M>2&:*GBQ,M>%017]O1=MF^[)O1F&S[Q:W9CIK\&6.73JK35H9M-:&E:5H:
M<#T*'MOHUZ][]U[KWOW7NO_1W^/?NO==$`@@_0@@_P"L>#[T0&!4C!Z]U5)D
MQ5=<]Y=:[HQ^,KL*E3NYMOUQ;:^^MO0Y/'562@Q=2KU^],WG3G&?&9`J#3/'
M"BQHP3E;<`=\&X>R_P!ZOV4YYV;8;K;8;CF'Z"<G;-]V]+FWDN([60&?>;Z^
M^N9K:X90;9HXD6.)A&-2$2G%HW'8]QMI)5<B+4.^)Z$`D8C5=.1YU)J<\>C"
M?,3L7KD;3SG4<NYL!)VM4;;QG8]%LL313[E@V3B]\;;VU7;KDI4627'8HY;-
M0T<<TIC^XD>1(M8CFT=%_P"\>V^*7[I//M_)9HS17NV:)"JDH[7]NO8Q%58H
M64E<Z25.&H0%REN^WKSC9;%]<G[U>VEF\$'O\):(9"!P76R@$TJ>%=)H6_X0
M00S=OY0S0Q2F'8^5DA,L:2&&0Y;!QF2(N"8Y#&Y74+'22/H3[YG_`-UE;6UQ
M]XO?FN+:.1H^5KMD+*&*-]78+J6H.EM+,NH4.EF%:$CJ0>=B1M$5"16=?^.M
MT-_S-R59E<]U+UU3_<R4.7R=7FLC14E#7962M:FFI*"B7^%8R2&OR(@AFJB(
MH661M7I(8`C*S^\NWK=-_P":ON^^S=F)WVG<;Z6\N888+BZ:8QO%!`/I;5DN
M+@(C77Z4+K(^JB,K`,"/DZ-(H-UW!J"1%"@DA:5J3W-4#\.3CUZ%S9?5V$WQ
MT\VQ-RXVIH=GYO,5G]Z]JG#[MVW#N;!PM#"VV,ICMXYK-9R+;67CI8XJZG68
M4]?1!J<J()I4?-O[INRIRU[3VMM!L;;<6OIV$+66[6!2@CB4BUWF\OKR,!(U
M"?K"$@`Q1J*U!O-UG#O4LEG>2^)9NJB10R,)%R3&S1JJE&)HXI5EJC$@D=&7
MIZ>"D@@I:6"&FI::&.GIJ:GC2&"G@A18X8((8U6.*&*-0JJH"JH``M[R1XY/
M'I(JJBJB*`@%`!@`#@`/3HN7R2^7_P`;_B#A-L[C^1_:.*ZNPN\<K683;5?E
M,3N7+)E<ICZ+^(UE)%'MK"9N>%X*+]PM*J(1P"3Q[?@MI[DL((]1''('^$CH
M.<R<X<N<H0VUQS'N:VT,S%4)61M1%*BD:L1Q'&@ST7[N+^;%_+]Z(GV72=C?
M(O;E%7[]VSMG>N"QF"P6\=VY6#:.\,739O;>X-Q8O:^WLM7[4I,MAZV&IABR
M<=+5/!(KB(KS[41;9?3:_#@/:2#4@9&#2ISGTZ#>]>[WMWL'T`W+F2-6N8TD
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M8Z6/&;MQNH^6-GA%K;AJ%4`X"I!)9J>M#]I/0DU/1'<'2?<.$JNJ*/.;NHUC
MI<E3Y2&&*@HZG'/4-#D]N[GJ9)H<5'Y%C(]3@.CI*BJZ^F;[O[I_WC/NP?>.
MY9OON_;?NG,6U*D=S'<(@MX)("Y2YV_<I&=;5=04@ZG`='BFC5)5`C+5WW:-
MZVB9=U9(I,@CB0:=KH/B_EQJ#4<;$^T*;:&0Z[W+3]A5,V*VA48V,;AJ(I9D
MFI*4U-,_IEH8JF;4M2$4F-7O_K>^ROOC9^WN[>SW.=I[O7LEA[>S6:?7R*SA
MXH_%B(HT*2O42Z%.A'K\P:]1[MK7<>X6[6"AKL,=(]30^M/+UZ"_J"MZ,Z^Z
MUWKN/KS<555["V[-F-R[MRU0N:R<F..'P--7Y61*9L8F3J138:D27Q4\,KN>
M$#.=/N+?N?[#]WG8^1>8K/[MO,,VY<IR;NS7#RM.Q6\-O;J4!N(8&`\$0G"E
M:D]U:@/\TWNX6Y:]Y@41"&`N2!6D:ZF)HFHFE#@5)I@=,?QJ^<7Q3^84^[:7
MXV]QX+M*IV+3X6KW73XO%;HQ$^(I=Q/D8\-42Q;FP6$>HAK9,34*&A$@0QV?
M266^7,]I<6P0S1Z0W#(/^`GJ/>6N>>5.<'O8^6]X2ZDM]/B`+(A746"_VB)6
MI4\*TIFE15GW7_,!^'VR?D'0?%7<W=N#Q_R!R>=VMMFAZTCP6\LCEIL]O6CQ
M^0VSC#7XO;=;@89\E0Y2GEO)5JL,<@:4Q@&UELKIX?J%B_1H36HX"M?.OD>F
M+OW#Y-L>84Y4N=[1>8&DCC$(25CKE"E%+*A0%@ZG+"@(K3JN3^9WUE_*1WE\
MCNM,O\\.WMR;![LH^O-N4FQL'A\WO[&TE=LR'?&Y:G"5TM/M;:6>QK2S[KFK
MH2\D\<I6,`J%"L5^WR;FD#BSC!AU&O#C0>I'RZC7W1VOV@O>9=OFY^W>2#?!
M:H(U4RT\(22E6[(G`)<R"NH'`]`>KP]S[GVYLG;><WAN[.8O;.U-KXBOSVXM
MPYNM@QN'PF%Q5+)69'*9.OJGCIZ.BHJ2%I))'8*JJ2?90JL[*B*2Q-`.IUNK
MJVL+6XO;RX2*TB0N[L0JJJBK,Q.``!4D]5,[Y_FC_`[Y/=+_`"@ZGZ;^0>VM
MQ;^?H#NZ+$;>RV(W1LZ?=G@ZWW,9ALZ;>6#P-+NJ0(I?PT3S5#1*9!&8P6!G
M'MUY;S6TLL!":US@TR.-":=0_N7NMR!S3L/-VS[+S%')N`VZZ`1EDC+GP),1
M^*B!SQPI)H":4'52W_"6-$5OFB555)IN@`=*@7LO;-KV'-K^S/F/"V0_TW^!
M>H?^Z@29^?234_XK_P`>NNMC?Y.?.SXF_#F'%?[,5W3MCK[)YZFEK,'MAXLK
MN'>.7HH9&A?(46T=K8_-;B.,\Z-&*MZ9*4RJ4\FH$>R"WL[F[)$$1;YX`_::
M#K)CFGG[E'DM(VYDWN*WD<55*,\C#A41QJSZ:XU%0M<5KTC_`(R?S)_A1\P-
MPS;-Z%[TP&Z=[PT51DO[D9;%[CV7NVJH*-==968K![RP^"K,Y!1Q>N<T(J/!
M'ZI-*\^[W&WW=J-4\)"^N"/Y$T_/I%RK[G<C<Z3FTY>WZ.:]`)\-E>*0@<2J
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M<%5$17?"*>"F[9S<U3-#3PQ[#RK/+/(D4:`9C`DEGD954`"_U^GO`+^ZUNK6
MR^\'S1=7MS'#;)RG=EG=E10/K-OR68@#\SU+?.RLVU0JJDMXZ\/]*_2U[LR]
M)V[WIB!M.EFW1MSK[#KCLQD\3AHMUXZ;*U4]=4M3QT'\;V_#E8/.T,!\=8G[
MB.RE@EC*OWH>8;'[Q7WJ>7HO;ZPDW[DOE';EM[RYM+)=VMVNI'N)3&L'UNWI
M=1ZVA@/AWB=ZRNFM4HR'986VG9)C=L(KF=ZJ&;PSI``K72Y4\3E?2M*]'UZN
MV\-L;%P&*^TIZ&7[>2NJ*6GPW]WU@GR,\M<T4N'_`(MG/L*J)9PDJ?=S#R*Q
MU<V'6?V)Y/7D7VJY2V#]W0VDW@M,\4=G^[PCW$C3E'L_J[[P)4$@25/JYAXB
ML0P!T@"[G<?4WUQ+K+"M`2VNM!3XM*U&,=HQTO\`W+O2#K5T_P"%0_\`S(OX
MJ?G_`(S!O3Z_^&*?8CY<_MY_L'^7K%+[UO\`RKG+'_/7)_QU>B]=F?RS_BM3
M?R/,?\I\7LG(-\CGZ/ZV[TR';.4W/G\EN#(9?*U>VGSNWIZ:HR!PJ[4&WJ^:
MAI*-*5?MTBADUM*A=GH]QN1O#0%QX&MEI0>5:?.M?\W#H.[I[6\IM[$0<SQV
M3_UC-E!<F=I'9BS,@==);1HT,54!<$!B2U23X?\`":G>F8W%\%^P-I92IEJ\
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MM[S_`/2L3_M*@Z(.6_\`DN;=_I_^?3T!_P`'*6GK>J]Z4=7#'4TE7O*NI:JG
MF4/%/3S[=PD4T,J-</'+&Y5@>"#[Q=_NG33V0]P"./\`6J3_`+0+'HYY\19-
MPMT=04:WH0>!!9JCK68_DY1U7P^_G(_(CXF9&5Z;%[DINYNK\3!+JBBK9>OM
MPIV%L')*DA6YJMAXRK>'ZEEJ^+W]]=]UI=[5!=#+#23\JX(_:W\NN=7LL'Y+
M]ZN8^3Y6TP2BY@0'\1B;Q8W_`#CB8C_3]1_Y<5"?FC_/>[P^1$Z-D]J=:[K[
MK[5QM1/^]`*#&U7^ASJJ'R"R"6#&92GJH+?\J)(_3?WN_/TFRPP#XF"@_;Q/
M^`_MZU[9QGG?W_WWF1QJM+66YG4^14'P(`3ZA9(V'^D^73/_`,*/O^W@GQR_
M\01L#_W\W8/NVP?[@7'_`#4/^!>DOWFO^GC<M_\`2NB_ZOW'5UG_``H2WIF]
MI?RUM[8[#5<U''OWLOJS9&<:"1HFJ,%49V3<=;1.RV9J>MFVU%'*GT>-F4W4
MD$FV-`VX(2.`)_R?Y>IV^\9?3V?MC?QP2%?'N88VH:'34R4^PF,5]1CAU5/\
M$_Y8WQ-[B_D]=A_(GLS8$V:[JR^U?D%O_;?8U)N'.XW/;.EZL?=&/VEC<)3T
MF03"#'+4[.,U5%44D_W7W<JN2!%XS2^W"ZBW:.!'I$"HI09U4_/@?7J(?;[V
MMY/WCV4W/F3<MN+[T\%Y*LH=PR&W\14"@'05U1U(937403A:*[_A+.Q>3YI,
M;7:#H)C;Z79>V2;?X<^Z\R&HLS_IO^?>E7W30%EY[4<`+3_#<]#_`-M?R4<G
MVW\X>ROF1\Z/D-USF_CGF-W[EW/F-H)G-S;(R.+V)04U1C>L-E9/>V7FQV+V
M_MS;E#'0QY!J:IIVF$4HBD1YFD">+=_"M$M;*!A/0"M`<XJ?G7/EY]"?>?8U
M]ZYYW'G3G_F*WDY<::1VCUO%IB[A#&TC!0@1?#5V#@D*=)!((HJ[X7XO]"?S
M5>ELS_+SWS1Y7JG!]H=$Y?$UVV=RYO<V#P.[ZW>=+A]Z[6PNY\O-45^<V]5X
M\@2_Y560/#7RP+*\8T*<PFYGVR87Z?J4(R`#]M/(_LZ@'?UY3Y=]WMBE]M]P
M#;4MS;N"CNZ*^L:T5VJ70TSW,"&*U(QU]#_V!>ND/7__T]_CW[KW12/FK\O-
MB_"WH[,]L;KHZO<NXZZMH]G]4=9X75+NGM;M'<!:FVGL7;E)#'/4RSY&L]=3
M*D<AIJ..64*[*D;J;6V>ZE$:X7B3Z#S/01YVYOL>2]CFW6[4R7+,(X(5^.>=
MO@C4`$Y.6(!(4$@,:*0`^'WQ*[2J^IMS;U^<V\,QV7WYWSNH=J;LVL<Q5KLW
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M6E@W<`0<*3ZD>7IT7WX[]4X7N'?%?M?/9+*XRAI=N5F9$V(:E2IEFIJ_&4JP
M.U93U40@9*UB?03=1[P\^YE]W_EG[Q_NGNO(O->];A8[9!LLUX'LS$)6>*XM
M8@A,T<J!")V)[":JM,5Z$',.ZS;18I<P1HSF0+1JTR&-<$>G5E?7OQ@Z>V%7
M4F<QF)J,_EJ1UFH,IN*N7+?:3)PM11TD45-BXJA&%TD$)DC(NK`CWW#]H_N)
M?=W]GMXLN8]HY:N-SYDMF#0W.Y2BY:)QD21PJD5LLBGN23P#)&P!1U(KU&E]
MS/NNXQM$\X2!N(04J/0FI-/E6A\^C%>\QNB#KWOW7NM73_A4/_S(OXJ?^)@W
MI_[PI]B/ES^WG^P?Y>L4OO6_\JYRQ_SUR?\`'%Z%SM7=VW,?_P`)N<36R9K%
MR4]=\/\`J79]+)#7TLR3;EK\CM#;8PD;12N'RM-EV>&:G'[L4D4BNJE&LS&C
M-OK``U\1C_(GH[W2]M8?NTVTKSIH.T6T=00>\O&FG_3!J@CB*&O`])O_`(33
M197%_"+O_.4N,DR#R?(;<LV(H_+]L,M68OJOKHFABJ&CE6(RU+I%KTL%9OH;
M6]EGN%?7^V[=NNX[3M9OMUM["66&V#^&;B5%=HX!(5<(97`0.5;3JKI-*=)O
MNGPD\F;R924A?=B-5.`\""I^=*]6_P#2_P`MH^QM[5VU]W8K"[)@J*+7MXRY
M&>26IR=/.5JL775M8M)3+524[:H4$499HW6Y8JOOE]]V;^\,MO>?W/W7D3W!
MV';>6+>6V)V\O<.6DN8WI);333>%'XC1G5$HBB):-TJSNB=9F[SRFVW6275K
M*\Q![Z#@",,`*FE>.3Q'SZ*7\O,?L?&]J*^Q'QZ5=7AX*[<M/A)(FHZ;<3U=
M3XY%6E)AI\C4TJQR3(ECJ*N1K<D\]O[Q79_:O9??^WE]JY;--PN-OCFW*.R9
M##'?M-+1@(CHCN)(A%),B4.HK*P\25B19RE)?2;61?!M(<A"W$K0>O$`U`K]
MG`='\[V:N?XT[M?)ZOXDVRL0V0UWU_?-+BC5Z[\ZO.6O_C[ZZ_>I?=)/N3\^
MR;YJ_?3<M69N-7'QR]H9:_/Q-5?GT`MCT#F.U$7]GXS4^SNI_+H+O@E_S+3=
M?_A\U'_N@P7O'_\`NGO^G'^X'_BU2?\`:!8]&O//_)2M?^:`_P"/-UJX?SKO
M[V_"G^:YUW\N>N:>*'*;]Z^P>_\`%RNDE/13[NVWA,QU%NJCFDB7UR/MM,=/
M+:Y)JQ?Z^^O>SA+S;GM9#A21^7'_``G^77-WWU:]Y#]VMOYSVN,":YMTE!.!
MXBJ8''^\(I/^GZ/'_P`)B>DWPG2?R(^0>2IBU;V-V%@^M<#6SI^])A.M\.^8
MS%1!(3=H,CN'>QCD/T,M!_5?:+F*:LT$`-0JDG\\?Y#^WH?_`'5]C,&Q<Q\Q
MR1D/=7*PK7^&)=;$?)C*H/S3Y=$=_P"%'W_;P3XY?^((V!_[^;L'VMV#_<"X
M_P":A_P+T`/O-?\`3QN6_P#I71?]7[CJX?\`X494=34_RXJN>")Y(L?WEU-6
M5KJ+BGII)<]CTED/X1JRNBCO_JG'LHV(_P"/C_2G_".IL^\I&[^V<C**A+V$
MGY#3(O\`A('Y]!I_+(W=MR7^0?OLOF,;31[3ZK^8.W=P355=34\&+RU15=BY
M6EHZV::5(Z6>JH=PT4D:.59UJ8R`=:W>W%6.]ICBR?RH/\AZ)_:R[M_^!XW$
M&91X5GN*O4@:6;QG`/H2LB$`_P`0]>BA_P#"646;YH`\$4_0((/X]/;/M3S'
M\-E_MO\``O0.^Z?F;GS_`*A?^/7/19\)G^R/YZ_\RO='3?:_;6XNOOC)UM/O
M[=.V^LMOY".C\>P=@[DQ^V*2GPN*J1+B<AV7O"?)T]3D,Q605<E!3-.($\4,
M,/M]DCV?;EFCB#7#4!)]3_D%,?EYFO0;M[O<_?OW1NMCW7=Y;;E:U\61(4-/
MTHV5`%!P9GU*7=@Q`UTJBJG1>?YB71OQY^-O\T;HKI;XU8?!X'8^QZSXSX_/
MXO$9^LW+70;\E[%:HSTF[,ID<CDZ]]VU5!+12U22R*R(\5HT4JOM1837$^VS
MRW!)8UIBF/E\N@U[D;!RWRS[M<N[)RO#''90?2JZJY<B762WB%F8ZR""0:4J
M,`8Z^@3[!'71+K__U-_<D*"S$*J@EF)```%R23P`![]U[JB_XJ8R;^8Y\U]]
M?._>RMD?C;\5MU;GZ0^$.U*M1+A<]O/#S)1=H?(F2DE'AJJVKR$:TF&J-!\:
M*EBD]`KL;W!^AM4M$_MY!J<^@\E_R'\_)NH)Y4B;W(YVON?+WNY:VN1K?;4.
M5=UIXMW3@:FAC/\`I00'@!-Z/LHZG;HE/S][1Z_ZL^.FX,IO[=.-V[%E<WM;
M%8"@G:2KS^ZLW+N'&-3;=V?MN@CJL]NW<=8!^S08^GJ*J3ZA+`D8G_?9]NN=
M?=?[O'-7(GM[R_-N?-5]>[:L,$>D5"W]N[N[NRQQQQHK/)([*B(I)..GK;FK
ME[D^ZAWCF3=([6Q4.`6J6=BI"QQ1J"\LC$@*D:LQ)X=$H^%FQM_[S[/K*KLL
M9WJ+$S[2K*VEZ6IJBEC['R^!&1P[)-WEF\=43IL-,K+-#)%L_&3-DEA0_P`8
MJXP[8UL4ON2^RWMI]WSWJW3D>^YY',/WB'Y=N)-Q2P(;:-EMA<66JR,K`/>;
MC)*T19P$C@2-AX89U=K[KN?-'.]A'NM[MLFT\F>,O@P28O;LT:DMR5)%M#2N
MFV0F1J_K2`5BZNHAAAIH8J>GBB@@@C2*&"&-8H88HU"1Q11(%2.-%``4```<
M>^KO25555"J`%`P!P'67W[K?7O?NO=:NG_"H?_F1GQ4_\3!O3_WA3[$?+G]O
M/]@_R]8I?>M_Y5SEC_GKD_XXO1?>MOY"=)\HOB7\6.S>HODONOJ3%]F=2]<]
M@]E=8;NQ^9[`V!+OO,;:I)LSO7:&,IMT;=CP^2R#S.STT\=2JL["*>&,B(/2
M;T;:[N5DMPQ5B`1@TKP/^K\N@]MGW?(^;.3.4MQVCF>:SAN;.&6:&13+&960
M:I$`=-).>TUXT#*M%&S!\*OB-U[\'_CQLOX]]<UF0S..VVV1RN?W5EXH(,QO
M+=^>JFKMP;FR--2EJ:C:LJ"L5/3H76EHX(8=<GC\C!^[NI+N=YY.)\O0?ZOY
M]90\D<G[;R+RY9<N[8S/%%5F=L-)(QJSD#AY*HJ=**JU)%2FNVOAKMS?F>KM
MT;4SQV?DLK.]7EL=+CADL+5ULS%ZBMIX8ZFCJ,?454A+RA6DC9R6"J2;\P?O
M#?W:_)?NSS;N?/?(/-9Y<WV_E,MU`UO]19RS.29)HU62&2WDE8EY0#)&SDLJ
M(2U9?VGG"XL8$M;J#QHE%%-:,!Y`X(('EP/S/43J[X6;<V?G:'<6\-PMN^IQ
M=3'68_$08U<9A5K('62GJ*]9:FMJ<B()5UK&3%&6`UAQZ?:#V'_NR.2O;;FK
M:^<_<7G!N8[^QF66WM4MQ;68E0AHWG#2S27`1AJ6.L498#Q%D2J&^Z<Y7-Y`
M]O:6_@HPH6K5J'B!@`5]<GTIT:3LO98[$V)N391R)Q(W#0K1'(K2BM-)IJ8*
MCR"E,],)K^"UO(OUO?WGC[V>V@]XO:OG/VS;>#MZ[O;+#]0(O&\*DL<FKPM<
M>NNBE-:\:UQT%]MO/W??6]YX>OPVK2M*X(XT/KZ=(OHKIQ>E=M97;J[@;<8R
M><DS7W;8P8LP^2@H:'[?PK75WD`^RU:M0_5:W%S%_P!U'[M:?=AY(Y@Y-3F\
M[R+[=6O?%-M]+HU000>'H\>?53P=6K4/BIIQ4KM\WC]]7,5P;?P]*::5U5R3
M7@/7HBW\T/\`E>X#^9/@NH:.I[2FZBW#U)F=TUE%N*GV5!O1LMA=W4&+I\G@
MYJ.3<>V7IE6OP5'4)*)I`#&RZ/7J&6VV[DVWM(1'J5J8K3A7Y'UZ@GW6]J;7
MW/MMHCDW3Z.YM&D*OX7BU631J6GB1TRBD&I\\9Z-#\'/BA@OA+\8^M_CC@MP
MMO%-CQY^HRN\9,-'M^?=.<W+N3+;DR>7GQ$>1RRT+&;*"!$^YF*PPH-1]IKR
MY:\N'N&6A-,>E!3_`&>A9R'RC;\C<K;;RS;7'C+!K)DTZ2[.[.3IU-2FK2!J
M.%&>B!_S'/Y.T'\P+Y`===ZR?("HZK;8&Q,!LH;9BZVAW@N4&#WEN'=PR1RT
MF]-NM1FI.>\'B^WD">+7J.K2%MANIL8)(/!U:FK6M/(#T/IU'7N7[+)[B\Q;
M=O[<PFT-O;)%H\'Q*Z9)'U:O%2E?$I32>%:YZLQ^4GQPV#\M>@NR/CUV6*Q-
MI]C8-<9/DL885R^!RM#64N7V]N3#O41S0+E-OYW'T]7"'5HY&BT.&1F!+[:X
M>UGCGC^)3_L$?F.I2YKY9V[G#E[<N7-T!^DN4I44U(RD,CK6HJCJK`'!I0U!
M/6OST'_PFWQ.Q]RY>#NKY3[C[+ZA-9+DZ/J7:FW,SL7;V[\U3021X#+=CP#>
M^5I,C#B*A897I:6*.6H\03[N..ZL=S[^T@!BMPLOJ37'G3'^KTZQWY=^[);[
M=<3Q[SS7+<[,6U"W1&C5W%=#2_J&H4T)5<FE-8ZL6_E;_P`K&+^6L_=+Q]W3
M]Q'N!-@J_FV!%L?^`G8_][/4OBW;NC^(_P`3_O3R#X?%X/[6KTH=RW([@(:Q
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M1W9JC?Y3%)%)`#7A0TH/3@:_;7I7+]V7:8=XVG==KYEEB-OH9Q)%XK2RJY9I
M"WBH$#5`"!#2E26))ZV8O8?ZR@Z__]7=>^5GR(ZM^-O7V`W1W-F1M?KK?._]
MN]29[=TTLE-CMIKOZER]#2YS+U\8)Q6+BJZ9(9:MK1TIF$KD(C$*+:"2=V6(
M5=5J!ZTICH+\V\Q[7RUMUO<[S+X>W7%PMN\G`1B57[V/X5%*%N"UJ<#HMG1G
M:7P9_E\?$_JWJFO^6'2:]>]:[:J:'#;KK=^[,_BF[H*W*Y/.S9J#"[>R^5J\
MYELI/DGEG:@BF^XG9G1%#!`_/'>7EQ)+],^H\<'%!3B?\O09V'=^0_;[E3:M
MH;FVP^AMT(5_%BU2:F9RRI&S%F8L2=`-3D#RZ+56?S.>^?F!DZG87\KCX[9K
M?6*EJ7QF5^7_`'_B,QU_\>=HH2\,^3V[B:J&GW1V'7TBL)(Z9$@G5U&JDFC)
M/M_Z"&V&N_F`/\"Y8_ZOV'^(=!Q_<_?N<)6L/:_EV2>*M&O[I6BM8^-2JGOD
M(_APZFA,3+T8'J'^7#5[6RB]R]R=];L[W^7>5I)J;)_(#>F$H*L=?8^OC(K]
MJ_'C8K52;8Z6V_(9&C>IQ\!RM2ER:B)7,8B?W@Y7YT]PN59N5.2/<>?E*.>J
MSW-K;)/=M$131%*\L?T['.J5`9:4"/&06([Y*Y)L-@W)>9>:I6WSFNF)IS2.
M$D4*V\(!2)?LR23P#:0,FV_AO5;/RKYW:_<^[<)F989X)LE18B@%3/#52)+4
M1U#2UL@J$FFC5V#AKNH;ZB_OG_R1_=N7OMOS%+S;R-]Y+?\`;>9)(WC>XAM(
MA)(DC!I%D)N#K5V568.""RJWQ`$35<\WK>0B"YV>)X00:%C0$<*8QT<W$4=3
MC\5C*"MR$^6K*+'T=)596I2.*IR5334\<,]?41Q?M1SUDB&1U7TAF(''OI3R
M[MM[L_+^Q[1N6\2[CN-K9PPRW4JJLES)'&J/<2*G:KS,#(ZKVAF(&.@?*ZR2
MR2)&$1F)"C@`3@#Y#ATX>SGIOKWOW7NJV?YDG\M_:G\Q[9?66S-U]H[FZOI^
ML]UYC=5)7;:P.(SLV5GR^%_@STE5%EIZ=*>*"/UJR$DMP>/:^POWL'=T0$L/
M\_V^O49^Y?MI9>Y5AMUC>[E););2,X*J&J6`&:LM*4]?/HWOQRZ9H/CKT-U%
MT1BL[6[GQO4G7^V=@T.X<E24]#7YFEVUC(,;#D:RCI'>FIJBJ2`,R1L54FP/
MM+/*9YI9B*%F)_;T,>6]DBY;V#:-AAG,D5G;I$&(H6""@)`)I7[3]O0T^VNC
MOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO_];=7^9G^RM?[+?V3_LYW]T?]EU_AU#_`'\_OG]__#/^
M+I1?P3[#^#?[^'^\7\<^W_AW\,_W(_>:/M_W+>U%K]1X\?TM?'\J?SXXI3C7
M'05YU_JI_5K<OZZ^#_5RB^+XFJGQ#1IT]^O7IT:._533GJA_XJ_]`TW]^Z+_
M`$:?Z'?[Z_?Q?PC_`&8C_2K_``?[KR#[?[+_`$\?[\+R>:VCR?O:K6]F]Q^_
M-/ZE:4_!IK_QC/4#<J?\#3]6O[N^F^HU"GUOU7AUJ*4^L_1XTI7->'6S/MS^
M[O\``<3_`'2_@O\`=C["G_@7]W/L?X#_``OQC[3^$_PS_<?]AXK>/P_MZ?T\
M>R%M6HZZZOGQZR<MOIOIX?H]'TND:-%-&GRTZ<4]*8Z>O>NG^O>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
B=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
